Reach Us +44-1904-929220
Inhibition Of Rosiglitazone On High Glucose And Advanced Glycation End Products Induced Proliferation In Colorectal Cancer Cells | 3620

Journal of Molecular Biomarkers & Diagnosis
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

3rd International Conference on Biomarkers & Clinical Research

Liang huasheng
Accepted Abstracts: J Mol Biomark Diagn
DOI: 10.4172/2155-9929.S1.015
Some epidemiological studies found that diabetes incidence rates of colorectal cancer was significantly higher than non-diabetic population. The receptor for advanced glycation end products (RAGE) was originally identified and chararized based on its ability to bind advanced glycation end products (AGEs), which were permanently modified protein derivatives forming glucose and fructose by nonenzymatic glycation and cxidation reactions and further irreversible rearrangements in diabetes. Recent studies showed that AGEs-RAGE was closely associated with carcinogenesis. This study aims to study whether rosiglitazone can inhibit SW480 from high glucose and advanced glycation end products induced proliferation. 45 cases of colorectal cancer tissue and adjacent tissues, 25 cases of colorectal cancer with diabetes and adjacent tissues specimens were analyzed for RAGE and AGEs expression using immuohistochemistry. Western blot of COX-2, NF-κB and Cyclin E in SW480 group, SW480 treated by advanced glycation end products group, SW480 treated by high glucose and advanced glycation end products group had carried out. Then cell viability, proliferation and apoptosis was used to measure MTT, BrdU and Annexin V, treatment of rosiglitazone were repeated with those groups after 72h. The results indicated that RAGE was highly expressed in colorectal cancer tissues and colorectal cancer with diabetes , but RAGE of colorectal cancer with diabetes adjacent tissues was higher than colorectal cancer adjacent tissues, which associated with deterioration of prognosis. Advanced glycation end products could increase cell viability, cell proliferation and decrease cell apoptosis in SW480, The expression of COX-2, NF-κB and Cyclin E were up-regulated by advanced glycation end products, Which effects of advanced glycation end products have increased in high glucose. However rosiglitazone could partly down-regulate the expression of COX-2, NF-κB and Cyclin E which un-regulated by advanced glycation end products under high glucose condition, and rosiglitazone could decrease cell proliferation and increase cell apoptosis induced by advanced glycation end products under high glucose. . The data from the current study suggest that targeting of RAGE expression by Rosiglitazone could effectively control colorectal cancer with diabetes in the future

Huasheng Liang, molecular biologist, graduated from Institute of Endocrinology and Metabolism disease, Southern Medical University in 2010. As a director he worked for Institute of Endocrinology and Metabolism disease, Ninth Affilicated Hospital of Guangxi Medical University, Beihai,Guangxi, P. R. China. Provided scientific and technical support of research activities to lab research projects, working with mouse models, cell culturing, immunoblotting, Bio-plex cytokine assays, immunopreciptation, flow cytometry, etc.. In recent year he focused on the diabetes and Cancer and got some important success. In some cancer and diabetes model, he can eliminate some cancer were induced by high glucose.

image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version